Clinical Trial Update: A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates [Phase 2]

View source ↗

Summary

A multicenter, single-arm Phase II exploratory trial evaluating eribulin plus anlotinib for HER2-negative recurrent/metastatic breast cancer in patients previou…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Eribulin (eribulin mesilate)

Snippet

Sponsor: Sun Yat-sen University | Conditions: HER 2 Negative Breast Cancer | Phase 2 | Status: RECRUITING